The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Subscribe To Our Newsletter & Stay Updated
